Oventus Medical Ltd. has announced significant progress has been made regarding the clinical validation of the Oventus O2Vent oral appliances and, in particular, validation of the benefit of the Oventus proprietary airway. A paper outlining the results of the pilot clinical trial, has recently been accepted as a peer reviewed article in the Journal of Dental Sleep Medicine (JDSM). This trial, on the Oventus O2Vent Monoblock appliances, showed that the O2Vent Mono is effective not only in the mild to moderate range of sleep apnoea but also in the moderate to severe range of sleep apnoea and was effective in reducing time under 90% O2 saturation for moderate to severe sufferers as well. 100% of patients involved in the trial experienced a significant improvement in snoring, and in 82% snoring was eliminated completely. The study highlighted that the O2Vent Mono can treat self-reported nasal obstructers as effectively as those with no nasal obstruction - a current unmet market need. The clinical trial in Brisbane, which is designed to assess the value of mandibular advancement alone versus mandibular advancement with the addition of the proprietary Oventus Airway Technology, has been fully recruited. The trial is anticipated to be completed in the coming quarter. An additional trial at Sir Charles Gairdner Hospital in Perth is now underway. This trial is focussing on specific pressure and flow measurements in the patient's airway at various levels of advancement. It is anticipated that both trials will be completed over the coming six months.